- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Option Bulls Take Another Shot on Idenix
- Top 20 European Stocks for Crisis Time: Strategist
- Hewlett-Packard Faces a ‘Dogfight’ for Talent: Analyst
- DuckDuckGo Cooks Google’s Goose: Analyst
- General Electric’s $4.5 Billion Dividend Slated for Buybacks
ABOUT THE CNBC STOCK BLOG
ART CASHIN
RSS FEED
CNBC Stock Blog
Text Size 
Stock Picker: Big Pharma, Big Opportunities
Health-care reform is not the only thing big pharmaceuticals have to fear, according to Deutsche Bank's Barbara Ryan. There's also the rapidly-growing dominance of generic prescription drugs. Still, she likes several big-name companies in the field.
"The industry is rapidly restructuring its cost base, and that's driving earnings up," she told CNBC Monday. "I think what we're going to see, in the not-too-distant future, is that the pharma industry gets a lot more aggressive about acquiring biotechnology, which is going to add to their revenue and earnings longer-term." (See her full comments in the video).
Recommendations:
Ryan likes Pfizer [PFE
Loading...
()
], Merck [MRK
Loading...
()
], and Bristol-Myers Squibb [BMY
Loading...
()
].
Among other things, she sees them involved in emerging markets to a much greater extent than the generic drugmakers.
Disclosures:
Ryan's firm owns more than one per cent of Pfizer, Merck and Bristol-Myers Squibb, and those companies are all investment banking clients of her firm.
Data is a real-time snapshot *Data is delayed at least 15 minutes
